Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-04-11 | H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH | NoNO (Canada) | acute ischemic stroke patients presenting within 3 hours of symptom onset |
Granting of the orphan status in the US |
2014-02-06 | DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor | ViroMed (South Korea) | amyotrophic lateral sclerosis |
Granting of the orphan status in the US |
2014-02-06 | engineered variant of recombinant human fibroblast growth factor 19 | NGM Biopharmaceuticals (USA - CA) | primary biliary cirrhosis |
Granting of the orphan status in the US |
2014-06-12 | Epstein-Barr virus-specific autologous cytotoxic T lymphocytes | FFCanVac Pte (Singapore) | Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma) |
Granting of the orphan status in the US |
2015-03-09 | autologous Epstein-Barr virus specific T-cells | Cell Medica (USA - TX) Cell Medica (UK) | Epstein-Barr virus positive non-Hodgkin lymphoma |
Granting of the orphan status in the US |
2014-12-22 | N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | Ignyta (USA - CA) Pharma Gateway (Sweden) | neuroblastoma | Granting of the orphan status in the EU |
2015-08-06 | fluticasone furoate and vilanterol | GSK (UK) Theravance (USA - CA) | asthma in adults 18 years of age and older |
Granting of a Market Authorisation in Canada |
2015-01-26 | idursulfase-IT | Shire (UK-USA) | neurocognitive decline associated with Hunter syndrome (mucopolysaccharidosis II or MPSII) |
Granting of a Fast Track status |
2017-05-31 | cetirizine | NicOx (France) | ocular itching associated with allergic conjunctivitis | Granting of a Market Authorisation in the US |
2015-01-30 | lubiprostone | Sucampo Pharmaceuticals (USA - MD) | chronic idiopathic constipation |
Granting of a Market Authorisation in the EU |
2017-07-20 | atezolizumab | Genentech (USA), a member of Roche Group (Switzerland) | metastatic bladder cancer urothelial carcinoma | Granting of a Market Authorisation in the EU |
2017-09-25 | atezolizumab | Roche (Switzerland) |
|
Granting of a Market Authorisation in the EU |
2015-03-20 | methylthioninium chloride hydrate | Daiichi Sankyo (Japan) | toxic methemoglobinemia |
Product launch |
2015-10-30 | aflibercept | Bayer Healthcare (Germany) | myopic choroidal neovascularization (mCNV) |
Granting of a Market Authorisation in the EU |
2015-02-06 | advanced genomic consulting service | Integragen (France) | Product launch | |
2014-02-06 | somatostatin analog | Andarix Pharmaceuticals (USA - MA) | small cell lung cancer |
Granting of a patent |
2014-06-19 | somatostatin peptide analogue | Andarix Pharmaceuticals (USA - MA) | pancreatic cancer |
Granting of the orphan status in the US |
2014-04-29 | recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase | Abeona Therapeutics (USA - OH) | mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A) |
Granting of the orphan status in the US |
2014-04-30 | recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase | Abeona Therapeutics (USA - OH) | mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B) |
Granting of the orphan status in the US |
2014-08-07 | N1,N14,-diethyl-3,12,-dihydroxyhomospermine | Sun BioPharma (USA - FL) | pancreatic cancer |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+